MX2021008914A - Derivados de salicilamina con trifenilfosfonio. - Google Patents

Derivados de salicilamina con trifenilfosfonio.

Info

Publication number
MX2021008914A
MX2021008914A MX2021008914A MX2021008914A MX2021008914A MX 2021008914 A MX2021008914 A MX 2021008914A MX 2021008914 A MX2021008914 A MX 2021008914A MX 2021008914 A MX2021008914 A MX 2021008914A MX 2021008914 A MX2021008914 A MX 2021008914A
Authority
MX
Mexico
Prior art keywords
salicylamine
derivatives
triphenylphosphonium
tethered
mitochondria
Prior art date
Application number
MX2021008914A
Other languages
English (en)
Inventor
Naji Abumrad
Kevin Moore
Michael P Murphy
Jr John Fuller
Original Assignee
Mti Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mti Biotech Inc filed Critical Mti Biotech Inc
Publication of MX2021008914A publication Critical patent/MX2021008914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los nuevos derivados de la salicilamina se dirigen directamente a las mitocondrias para aumentar la eficacia y reducir las dosis requeridas en el tratamiento de afecciones causadas por la inflamación o el estrés oxidativo.
MX2021008914A 2019-01-25 2020-01-27 Derivados de salicilamina con trifenilfosfonio. MX2021008914A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962796999P 2019-01-25 2019-01-25
PCT/US2020/015221 WO2020154731A1 (en) 2019-01-25 2020-01-27 Triphenylphosphonium-tethered salicylamine derivatives

Publications (1)

Publication Number Publication Date
MX2021008914A true MX2021008914A (es) 2021-11-04

Family

ID=71737017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008914A MX2021008914A (es) 2019-01-25 2020-01-27 Derivados de salicilamina con trifenilfosfonio.

Country Status (9)

Country Link
US (1) US20220112152A1 (es)
EP (1) EP3914359A4 (es)
JP (1) JP2022518875A (es)
CN (1) CN113939342A (es)
AU (1) AU2020212612A1 (es)
BR (1) BR112021014697A2 (es)
CA (1) CA3127783A1 (es)
MX (1) MX2021008914A (es)
WO (1) WO2020154731A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240093087A (ko) * 2022-12-15 2024-06-24 주식회사 스마틴바이오 Trap-1 억제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL173807A (en) * 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
GB201320636D0 (en) * 2013-11-22 2014-01-08 Medical Res Council Compounds
EP3615015B1 (en) * 2017-04-27 2024-03-13 Vanderbilt University Gamma-ketoaldehyde scavengers for treating atherosclerosis
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法

Also Published As

Publication number Publication date
JP2022518875A (ja) 2022-03-16
US20220112152A1 (en) 2022-04-14
WO2020154731A1 (en) 2020-07-30
AU2020212612A1 (en) 2021-08-19
EP3914359A1 (en) 2021-12-01
BR112021014697A2 (pt) 2021-09-28
CA3127783A1 (en) 2020-07-30
EP3914359A4 (en) 2022-11-09
CN113939342A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201600235A1 (ru) Циклические пептидомиметические соединения в качестве иммуномодуляторов
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
BR112022003527A2 (pt) Cianopirrolidinas substituídas com atividade como inibidores de usp30
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2021000007A1 (es) Tiofeno carboxamida sustituida y analogos como agentes antibacterianos
UY30918A1 (es) Moduladores de lta4h y sus usos
EA202193111A1 (ru) Композиции и способы для лечения рака
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
CL2021000529A1 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
CL2022001006A1 (es) Inhibidores de tim-3 y sus usos
MX2021008914A (es) Derivados de salicilamina con trifenilfosfonio.
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.